Massa Scott, Smits David J, Nguyen Alexander T, Patil Sachi A, Chen Evan M, Shorstein Neal H, Friedman Scott, Parikh Ravi
From the Department of Ophthalmology, New York University Grossman School of Medicine, New York, New York (Massa, Patil, Parikh); Cheyenne Eye Clinic and Surgery Center, Cheyenne, Wyoming (Smits); Department of Ophthalmology, Yale New Haven Health, New Haven, Connecticut (Nguyen); The Eye Care Group, Waterbury, Connecticut (Nguyen); Department of Ophthalmology, University of California, San Francisco School of Medicine, San Francisco, California (Chen); Seva Foundation, Berkeley, California (Shorstein); Florida Retina Consultants, Lakeland, Florida (Friedman); Manhattan Retina and Eye Consultants, New York, New York (Parikh).
J Cataract Refract Surg. 2024 Dec 1;50(12):1215-1223. doi: 10.1097/j.jcrs.0000000000001526.
To determine whether dropless, injection-based cataract surgery prophylaxis with intracameral antibiotic and subconjunctival steroid may reduce healthcare system costs and patient out-of-pocket costs compared with topical medication regimens.
U.S. national medical expenditures database.
Retrospective cost analysis.
Costs were analyzed for topical ophthalmics from the 2020 Medical Expenditure Panel Survey (MEPS) and for dropless medications from pharmaceutical invoices/catalogs. Main outcomes included system costs, from insurance and patient payments, and out-of-pocket costs for cataract surgery topical and dropless, injection-based prophylactic medication regimens, per eye and nationally. System costs for individual topical medications and same-class dropless, injection-based medications were compared using 2-sided, 1-sample t tests.
There were 583 prophylactic topical ophthalmic purchases in MEPS. Mean system costs per eye were $76.20 ± SD 39.07 for the lowest cost topical steroid (prednisolone) compared with $4.01 for the lowest cost subconjunctival steroid (triamcinolone acetonide) ( P < .001). Per eye, the lowest cost dropless, injection-based regimen, at $15.91, results in an $87.99 (84.7%) reduction in overall healthcare costs and a $43.64 (100%) reduction in patient out-of-pocket costs relative to the lowest cost topical regimen ($103.90 ± 43.14 mean system cost and $43.64 ± 37.32 mean out-of-pocket cost per eye). Use of intracameral moxifloxacin and subconjunctival triamcinolone acetonide can reduce annual national healthcare system and out-of-pocket costs up to $450 000 000 and $225 000 000, respectively.
An evidence-based cataract surgery prophylactic medication regimen of intracameral moxifloxacin and subconjunctival triamcinolone acetonide can reduce healthcare system and patient out-of-pocket costs in comparison with various topical regimens.
确定与局部用药方案相比,采用前房内抗生素和结膜下类固醇的无滴剂、基于注射的白内障手术预防措施是否可以降低医疗系统成本和患者自付费用。
美国国家医疗支出数据库。
回顾性成本分析。
从2020年医疗支出面板调查(MEPS)中分析局部眼科用药的成本,并从药品发票/目录中分析无滴剂药物的成本。主要结果包括保险和患者支付产生的系统成本,以及白内障手术局部和无滴剂、基于注射的预防用药方案的每只眼和全国范围内的自付费用。使用双侧单样本t检验比较了个体局部用药和同类无滴剂、基于注射的药物的系统成本。
MEPS中有583次预防性局部眼科用药购买。每只眼,成本最低的局部类固醇(泼尼松龙)的平均系统成本为76.20美元±标准差39.07美元,而成本最低的结膜下类固醇(曲安奈德)为4.01美元(P < .001)。每只眼,成本最低的无滴剂、基于注射的方案为15.91美元,相对于成本最低的局部方案(每只眼平均系统成本103.90美元±43.14美元,平均自付成本43.64美元±37.32美元),总体医疗成本降低87.99美元(84.7%),患者自付成本降低43.64美元(100%)。使用前房内莫西沙星和结膜下曲安奈德每年可分别降低国家医疗系统成本和自付费用高达4.5亿美元和2.25亿美元。
与各种局部用药方案相比,基于证据的前房内莫西沙星和结膜下曲安奈德白内障手术预防用药方案可降低医疗系统成本和患者自付费用。